Kinnate Biopharma Inc (DELISTED) (KNTE:DL)
2.65
0.00 (0.00%)
USD |
NASDAQ |
Apr 03, 16:00
Kinnate Biopharma Research and Development Expense (TTM): 90.77M for Dec. 31, 2023
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | 90.77M |
| September 30, 2023 | 102.58M |
| June 30, 2023 | 101.62M |
| March 31, 2023 | 95.06M |
| December 31, 2022 | 88.15M |
| September 30, 2022 | 82.49M |
| June 30, 2022 | 77.67M |
| Date | Value |
|---|---|
| March 31, 2022 | 74.15M |
| December 31, 2021 | 67.17M |
| September 30, 2021 | 59.61M |
| June 30, 2021 | 49.37M |
| March 31, 2021 | 38.70M |
| December 31, 2020 | 29.24M |
| September 30, 2020 | 20.32M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
20.32M
Minimum
Sep 2020
102.58M
Maximum
Sep 2023
69.78M
Average
75.91M
Median
Research and Development Expense (TTM) Benchmarks
| XOMA Corp | 0.122M |
| Societal CDMO Inc (DELISTED) | -- |
| NGM Biopharmaceuticals Inc (DELISTED) | 118.04M |
| Avrobio Inc | 31.05M |
| Landos Biopharma Inc (DELISTED) | 11.82M |